<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509301</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 0602</org_study_id>
    <nct_id>NCT00509301</nct_id>
    <nct_alias>NCT00516789</nct_alias>
  </id_info>
  <brief_title>Safety &amp; Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>Open-label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine
      131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor
      cells and deliver radiation directly to the center of the tumor mass while minimizing effects
      on normal tissues. Cotara® thus literally destroys the tumor &quot;from the inside out.&quot; This may
      be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.

      PURPOSE: This trial is studying the safety and radiation distribution of Cotara® in patients
      with recurrent glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To confirm the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of
           131I-chTNT-1/B MAb (Cotara®) when given as a single 25 hour interstitial infusion in
           patients with recurrent GBM

        -  To characterize the biodistribution and radiation dosimetry of Cotara®

      OUTLINE:

      This is an open-label, dose escalation study of Cotara®.

      All patients will receive 3 mCi of Cotara® for biodistribution and radiation dosimetry
      purposes. In addition, patients will receive escalating therapeutic dose levels of Cotara®
      for confirmation of the maximum tolerated dose (MTD). After completion of study treatment,
      patients are followed for a minimum of 12 weeks and until disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To confirm dose limit and maximum tolerated dose and to characterize radiation distribution</measure>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Recurrent Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mCi/cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mCi/cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mCi/cc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>131-I-chTNT-1/B MAB</intervention_name>
    <description>The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Cotara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with recurrent GBM

          -  Patients with a Clinical Target Volume between 5 and 60 cc (inclusive)

          -  Patients of 18 years of age or older

          -  Karnofsky Performance Status ≥ 60 at screening

          -  Patients not on steroids or maintained on a stable corticosteroid regimen (± 4 mg) for
             at least 2 weeks prior to study entry

        Exclusion Criteria:

          -  Patients with infratentorial tumor(s), exophytic intra-ventricular tumor(s) or
             subependymal tumor spread extending greater than 2 cm

          -  Patients with diffuse disease

          -  Patients with known or suspected allergy to study medication or iodine

          -  Patients who received investigational agents within 30 days prior to baseline

          -  Patients who received surgical resection within 4 weeks from baseline

          -  Patients with known HIV or evidence of active hepatitis

          -  Patients who cannot undergo MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil J Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth M Spicer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin D Judy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William R Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Neurological Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew E Sloan, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jennifer Lai, MBA, CCRA</name_title>
    <organization>Peregrine Pharmaceuticals</organization>
  </responsible_party>
  <keyword>brain cancer</keyword>
  <keyword>Cotara</keyword>
  <keyword>radioactive isotope</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>radiation distribution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

